Comparative Pharmacology
Head-to-head clinical analysis: OSMOVIST 190 versus SCANLUX 300.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OSMOVIST 190 versus SCANLUX 300.
OSMOVIST 190 vs SCANLUX-300
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast media with high osmolality, providing radiographic contrast by attenuating X-rays, primarily due to iodine content.
SCANLUX-300 (gadoxetate disodium) is a hepatobiliary MRI contrast agent that shortens T1 relaxation time, enhancing signal intensity in tissues. It is taken up by hepatocytes via OATP1B1/1B3 transporters and excreted into bile via MRP2, allowing both dynamic and hepatobiliary phase imaging.
Intravenous administration of 0.1-0.3 mL/kg (0.19-0.57 mg iodine/kg) for adults; may repeat as needed. Maximum total dose 1.5 mL/kg.
30 mg/m² IV over 1 hour every 4 weeks.
None Documented
None Documented
Terminal elimination half-life approximately 110 minutes. In renal impairment, half-life is prolonged, requiring dose adjustment.
Terminal elimination half-life is 3.5 hours (range 2.8–4.5 h); may be prolonged in hepatic impairment (up to 7 h).
Primarily renal (glomerular filtration). Excreted unchanged in urine, with less than 2% biliary/fecal excretion.
Renal excretion of unchanged drug accounts for approximately 30% of the administered dose; fecal/biliary elimination accounts for about 60% (via hepatobiliary secretion into feces); minimal excretion via other routes.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent